RNA Based Therapeutics and Vaccines Market size was valued at USD 61,296.3 million in 2021 and is expected to grow at a significant CAGR of 3.8% over 2022-2028. Global RNA based therapeutics and vaccines market is likely to experience a steep rise in its growth during the forecast period due to the rise in prevalence of chronic diseases such as diabetes, tuberculosis, cancer, and certain other cardiovascular conditions. RNA therapeutics and vaccines hold the distinction of providing better stability as compared to their counterparts. Though majority of them are under trials (as mentioned above), they are being increasingly preferred when it comes to treat obstinate disorders. Rapid advancement in technologies particularly in the healthcare sector has significantly lifted the demand for RNA based therapeutics and vaccines.  Healthcare sector have been bringing their minds together to bring stability to the RNA molecules in the body with limited bioavailability. It is the RNA therapeutics which when combined with protein/ lipid nanoparticles provide better stability. In spite of being in a clinical research phase the RNA therapeutics has been extensively explored with a primary aim to treat difficult diseases. One of the major factors which is driving the market is the rise of promising technologies such as antisense technology, smart technology, and RNAi interference technology. The RNA based therapeutics and vaccine market primarily find cures for cancer and infectious diseases and since the pool of patients is large, the demand for the market subsequently is also high. This creates a huge opportunity globally for RNA based Therapeutics and Vaccines market. The lack of alternative treatment options for rare diseases further boosted the growth of RNA-based therapeutics and vaccines during the forecast period. Aiding the growth of this market, increasing focus of legislative bodies on developing reimbursement policies has fueled the development process RNA’s molecules. Recent Market Developments: In Jan 2022, Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease. Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers. In April 2020, Blackstone and Alnylam Entered Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics